INKT cells suppress the CD8+ T cell response to a murine burkitt's-like b cell lymphoma

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Bjordahl, Ryan L ^a   Gapin, Laurent ^a   Marrack, Philippa ^a,b   Refaeli, Yosef ^a,c  

^a UNIVERSITY OF COLORADO   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD8 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER TRANSPLANTATION; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL GROWTH; CELL INTERACTION; CELL SPECIFICITY; CELL TYPE; CELLULAR IMMUNITY; CONTROLLED STUDY; IMMUNOSTIMULATION; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOMA CELL; MOUSE; NATURAL KILLER T CELL; NONHUMAN; T LYMPHOCYTE ACTIVATION; WILD TYPE;

ANIMALS; ANTIGENS, NEOPLASM; BURKITT LYMPHOMA; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; GALACTOSYLCERAMIDES; GRAFT REJECTION; IMMUNIZATION; MICE; MICE, INBRED C57BL; NATURAL KILLER T-CELLS; NEOPLASM TRANSPLANTATION; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES, CYTOTOXIC; TUMOR BURDEN;

MURINAE; MUS;

EID: 84864720683     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042635     Document Type: Article

References (42)

1. Nishikawa H, Sakaguchi S, ((2010)) Regulatory T cells in tumor immunity. Int J Cancer 127:: 759--767.
2. Terabe M, Berzofsky JA, ((2008)) The role of NKT cells in tumor immunity. Adv Cancer Res 101:: 277--348.
3. Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L, ((2008)) CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system. Curr Opin Immunol 20:: 358--368.
4. Cardell S, Tangri S, Chan S, Kronenberg M, Benoist C, et al. ((1995)) CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice. J Exp Med 182:: 993--1004.
5. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L, ((2004)) NKT cells: what's in a name? Nat Rev Immunol 4:: 231--237.
6. Dellabona P, Padovan E, Casorati G, Brockhaus M, Lanzavecchia A, ((1994)) An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells. J Exp Med 180:: 1171--1176.
7. Burdin N, Brossay L, Koezuka Y, Smiley ST, Grusby MJ, et al. ((1998)) Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes. J Immunol 161:: 3271--3281.
8. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, et al. ((1997)) CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278:: 1626--1629.
9. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y, ((1995)) KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 7:: 529--534.
10. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, et al. ((1999)) Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 163:: 4647--4650.
11. Liu K, Idoyaga J, Charalambous A, Fujii S, Bonito A, et al. ((2005)) Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J Exp Med 202:: 1507--1516.
12. Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, et al. ((2005)) A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 202:: 1627--1633.
13. Ambrosino E, Terabe M, Halder RC, Peng J, Takaku S, et al. ((2007)) Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol 179:: 5126--5136.
14. Renukaradhya GJ, Khan MA, Vieira M, Du W, Gervay-Hague J, et al. ((2008)) Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood 111:: 5637--5645.
15. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, et al. ((1985)) The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318:: 533--538.
16. Refaeli Y, Young RM, Turner BC, Duda J, Field KA, et al. ((2008)) The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas. PLoS Biol 6:: e152.
17. Refaeli Y, Field KA, Turner BC, Trumpp A, Bishop JM, ((2005)) The protooncogene MYC can break B cell tolerance. Proc Natl Acad Sci U S A 102:: 4097--4102.
18. Bendelac A, Killeen N, Littman DR, Schwartz RH, ((1994)) A subset of CD4+ thymocytes selected by MHC class I molecules. Science 263:: 1774--1778.
19. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, et al. ((2001)) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:: 1107--1111.
20. Cui J, Shin T, Kawano T, Sato H, Kondo E, et al. ((1997)) Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278:: 1623--1626.
21. Ostrand-Rosenberg S, ((2008)) Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 18:: 11--18.
22. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, et al. ((2007)) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:: 903--907.
23. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, et al. ((1996)) Phenotypic analysis of antigen-specific T lymphocytes. Science 274:: 94--96.
24. Mallevaey T, Fontaine J, Breuilh L, Paget C, Castro-Keller A, et al. ((2007)) Invariant and noninvariant natural killer T cells exert opposite regulatory functions on the immune response during murine schistosomiasis. Infect Immun 75:: 2171--2180.
25. Halder RC, Aguilera C, Maricic I, Kumar V, ((2007)) Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest 117:: 2302--2312.
26. Mars LT, Laloux V, Goude K, Desbois S, Saoudi A, et al. ((2002)) Cutting edge: V alpha 14-J alpha 281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J Immunol 168:: 6007--6011.
27. Hammond KJ, Poulton LD, Palmisano LJ, Silveira PA, Godfrey DI, et al. ((1998)) alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 187:: 1047--1056.
28. Zintzaras E, Voulgarelis M, Moutsopoulos HM, ((2005)) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165:: 2337--2344.
29. Cuttner J, Spiera H, Troy K, Wallenstein S, ((2005)) Autoimmune disease is a risk factor for the development of non-Hodgkin's lymphoma. J Rheumatol 32:: 1884--1887.
30. Santana V, Rose NR, ((1992)) Neoplastic lymphoproliferation in autoimmune disease: an updated review. Clin Immunol Immunopathol 63:: 205--213.
31. Swann JB, Uldrich AP, van Dommelen S, Sharkey J, Murray WK, et al. ((2009)) Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood 113:: 6382--6385.
32. Smyth MJ, Crowe NY, Godfrey DI, ((2001)) NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 13:: 459--463.
33. Berzofsky JA, Terabe M, ((2009)) The contrasting roles of NKT cells in tumor immunity. Curr Mol Med 9:: 667--672.
34. Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, et al. ((2002)) Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood 99:: 1259--1266.
35. Terabe M, Khanna C, Bose S, Melchionda F, Mendoza A, et al. ((2006)) CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta. Cancer Res 66:: 3869--3875.
36. Renukaradhya GJ, Sriram V, Du W, Gervay-Hague J, Van Kaer L, et al. ((2006)) Inhibition of antitumor immunity by invariant natural killer T cells in a T-cell lymphoma model in vivo. Int J Cancer 118:: 3045--3053.
37. Mattarollo SR, Rahimpour A, Choyce A, Godfrey DI, Leggatt GR, et al. ((2010)) Invariant NKT cells in hyperplastic skin induce a local immune suppressive environment by IFN-gamma production. J Immunol 184:: 1242--1250.
38. Yang W, Li H, Mayhew E, Mellon J, Chen PW, et al. ((2011)) NKT cell exacerbation of liver metastases arising from melanomas transplanted into either the eyes or spleens of mice. Investigative ophthalmology & visual science 52:: 3094--3102.
39. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, et al. ((2000)) NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1:: 515--520.
40. Butcher BW, Collins RH Jr, ((2005)) The graft-versus-lymphoma effect: clinical review and future opportunities. Bone marrow transplantation 36:: 1--17.
41. Grigg A, Ritchie D, ((2004)) Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 10:: 579--590.
42. Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, et al. ((2012)) Burkitt's lymphoma. Lancet 379:: 1234--1244.